Pardoprunox (SLV-308), which is agonist of D2/D3 receptors and full agonist of 5-HT1A receptor, reached the phase III clinical trial for the treatment of early stage PD with low side effects, like psychosis or dyskinesia [7]. Here, HTR1A is linked to drug-induced dyskinesia.